Encora Therapeutics
Founded 2018 · 18 employees on LinkedIn · 4 known investors
Find your way into Encora Therapeutics
373 people in our graph share verified history with the Encora Therapeutics team — schools, employers, funds. One of them is your warm intro.
Encora Therapeutics makes the Encora X1, an FDA-cleared, prescription wrist-worn device that uses mechanical neurostimulation to relieve hand tremors in adults with essential tremor. The device is designed as a non-drug option that can be used alone or alongside existing treatment plans.
Also known as Encora X1
Founders & leadership
Encora Therapeutics was founded in 2018 by Daniel Carballo, Allison Davanzo, and Kyle Pina.
Investors · 4
Company profile
researched Aug 2026Encora Therapeutics develops the Encora X1, a wrist-worn medical device intended to aid in the relief of hand tremors in the treated limb during stimulation in adults with essential tremor. The device is FDA-cleared and available by prescription only. It applies gentle mechanical neurostimulation rather than electrical stimulation and is designed to be worn and kept on throughout the day so that relief and fine motor support are available as needed.
The company positions Encora X1 as a non-drug, non-surgical option that can be used on its own, alongside an existing treatment plan, or as an alternative when medication is not appropriate. Because the therapy is mechanical rather than electrical, the company states there are no electrical contraindications, and the device can be considered for people with pacemakers, ICDs, insulin pumps and other implanted electrical devices; compatibility is supported by bench testing conducted per IEC 60601-1-2, with three participants who had implanted electronic devices included in the 90-Day Home Use Study. The company also notes that Encora X1 is not a cure for essential tremor and that reported device-related adverse events in clinical trials were non-serious, temporary and self-resolving, including numbness (3%), buzzing or tingling (3%), discomfort or pain (1.5%), and skin irritation, muscle weakness and temporary worsening of tremor each under 1%.
Business model
Encora Therapeutics sells a prescription medical device directly to patients, supported by an in-house Patient Advocate function that assists with insurance coverage, onboarding and ongoing support. At the time of the source, access is managed through a waitlist ahead of commercial availability.
Traction
In the ULTRE clinical trial, 70-75% of device users achieved meaningful tremor improvement compared with 48% of the sham group. A pooled responder rate of 78% was observed after 90 days of use across both cohorts, and 96% of participants rated the therapy as comfortable all of the time. The company reports patient testimonials from participants in the Encora X1 90-Day Home Use Study and is collecting waitlist registrations ahead of availability.
Latest developments
Encora X1 is FDA-cleared and the company is operating a waitlist, contacting registrants regarding fit, coverage and prescription when the device becomes available.
▸Full profile — market position, technology, go-to-market, geography
Market position
Encora Therapeutics competes in the FDA-cleared wearable tremor-relief category for essential tremor, positioning its product between pharmacological treatment and surgical intervention.
The company differentiates Encora X1 from other FDA-cleared tremor wearables by its use of mechanical rather than electrical neurostimulation, its all-day wear design, and the absence of electrical contraindications, which allows consideration for patients with pacemakers, ICDs, insulin pumps and other implanted electrical devices.
Technology
Encora X1 is a wrist-worn wearable that uses mechanical neurostimulation to relieve hand tremors during stimulation, distinguishing it from electrical stimulation tremor wearables. Device effects were observed in approximately 15 minutes. The product was designed at MIT and is manufactured in the United States.
Go-to-market
Direct-to-patient marketing through the company website with a waitlist sign-up, combined with a required prescription pathway involving the patient's healthcare provider. Encora Patient Advocates guide fit, insurance coverage and onboarding.
Adults diagnosed with essential tremor who experience hand tremor affecting fine motor tasks, including patients seeking a non-drug or non-surgical option, patients continuing medication, and their caregivers. Prescribing clinicians are a necessary channel because the device is Rx only.
Geography
United States; the device is designed at MIT and manufactured in the U.S.A.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsThe Encora X1 wrist-worn neurostimulation device is FDA-cleared and available by prescription, indicated to aid in the relief of hand tremors in the treated limb during stimulation in adults with essential tremor.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 1
primary sources listed
- Encora Therapeuticsencoratherapeutics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Encora Therapeutics do?
- Encora Therapeutics makes the Encora X1, an FDA-cleared wrist-worn mechanical neurostimulation device for essential tremor.
- Who founded Encora Therapeutics?
- Encora Therapeutics was founded by Daniel Carballo, Allison Davanzo, Kyle Pina in 2018.
- Who are Encora Therapeutics's investors?
- Encora Therapeutics's investors include Good Growth Capital, Innospark Ventures, Safar Partners, SBXi.